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The interaction between the T-lymphocyte costimulatory molecule ICOS and its ligand (ICOS-L)
is needed for efficient immune responses, but expression levels are tightly controlled, as altered
expression of ICOS or ICOS-L may lead to immunodeficiency, or favor autoimmune diseases and
tumor growth.
Using cells of mouse B cell lymphoma (M12.C3) andmelanoma (B16), or hamster CHO cells trans-
fected with various forms of mouse ICOS-L, and ICOS+ T cell lines, we show that, within minutes,
ICOS induces significant downmodulation of surface ICOS-L that is largely mediated by endocy-
tosis and trans-endocytosis. So, after interaction with ICOS+ cells, ICOS-L was found inside per-
meabilized cells, or in cell lysates, with significant transfer of ICOS from ICOS+ T cells to ICOS-L-
expressing cells, and simultaneous loss of surface ICOS by the T cells. Data from cells expressing
ICOS-L mutants show that conserved, functionally important residues in the cytoplasmic domain
of mouse ICOS-L (Arg300, Ser307 and Tyr308), or removal of ICOS-L cytoplasmic tail have minor
effect on its internalization.
Internalization was dependent on temperature, and was partially dependent on actin polymer-
ization, the GTPase dynamin, protein kinase C, or the integrity of lipid rafts. In fact, a fraction of
ICOS-L was detected in lipid rafts. On the other hand, proteinase inhibitors had negligible effects
on early modulation of ICOS-L from the cell surface.
Our data add a new mechanism of control of ICOS-L expression to the regulation of ICOS-
dependent responses.
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1 INTRODUCTION
Adaptive immune responses to pathogens or tumors are initiated by
antigen recognition through antigen-specific receptors in the mem-
braneof T andB lymphocytes.However, in addition to antigen receptor
signals (signal 1), the development of efficient immune responses need
additional signals delivered by interaction of costimulatory molecules
in the membrane of lymphocytes and antigen-presenting cells (APC)
(signal 2), plus signals induced by cytokines and chemokines (signal 3).
Together, these signals induce the expansion of antigen-specific lym-
phocytes, their differentiation into effector and memory cells, and its
adequate location to remove antigens.
The inducible costimulator (ICOS, H4, CD278) belongs to the CD28
family of regulators of immune responses.1–3 This family includes cos-
timulatory molecules that foster antigen activation of T lymphocytes
(CD28, ICOS) as well as negative regulators of immune responses like
CTLA-4, PD-1, or BTLA-4. Their ligands belong to the B7 family, so
that CD28 and CTLA-4 bind B7-1 (CD80) and B7-2 (CD86), and ICOS
binds the ICOS ligand (ICOS-L, B7h, CD275, GL50, B7RP-1, LICOS,
B7-H2).
ICOS is characteristically expressed by activated T cells, where it
serves as a costimulatory molecule promoting the differentiation of
effector Th cells and enhancing the secretion of cytokines like IL-10,
IL-17 and IFN- in humans, or IL-4 in mice.4–7 Follicular helper CD4+
T cells (Tfh) express the highest levels of ICOS, and ICOS is essen-
tial to the development of germinal centers, the cooperation with B
cell activation, isotype switch, and maturation of normal or autoim-
mune antibody responses, so that ICOS deficiency is a cause of human
immunodeficiency.8–13 ICOS ligation also induces T cell motility14–16
that contributes to germinal center formation.17 Furthermore, ICOS
signals promote the survival of effector memory and Treg CD4+
T cells.18,19 Last, recent data show the expression of and a role for
ICOS in the function and/or survival of leukocytes other than T lym-
phocytes, including dendritic cells (DC)20 or innate lymphoid cells
(ILC).21–23
On the other hand, the ICOS-L is expressed by cells of hematopoi-
etic and non-hematopoietic origin. These include professional APC
(DC, macrophages and B lymphocytes), and a subset of T lymphocytes
and ILC. Among non-hematopoietic cells, ICOS-L can be expressed by
fibroblasts, epithelial cells and vascular endothelial cells, aswell as var-
ious types of tumor cells and tumor cell lines.7,24–31
A prime function of ICOS-L is the induction of ICOS-mediated cos-
timulatory signals in T cells during antigen responses “in vivo” and “in
vitro7,28,32–34”. Furthermore, ICOS-L expression by non-professional
APC allows ICOS-mediated regulation of antigen activation, i.e. in
experienced effector/memory T cells.26,27
In addition, ICOS-L itself delivers signals in ICOS-L expressing
cells including DC, the prototypic professional APC. In mouse DC,
ICOS-L signals induce interleukin 6 (IL-6), and enhance phagocytosis
and antigen-presentation.35 Our results in monocyte-derived human
DC show that ICOS-L signalling enhanced LPS-induced secretion of
cytokines IL-10 and IL-23, antigen cross-presentation by class I MHC,
DC adhesion to endothelial cells, or chemokine-induced migration36;
similar conclusions have been reached by Hedl et al.20 Interaction
with ICOS also inhibited the migration of ICOS-L+ non-hematopoietic
cells including endothelial cells and different types of tumor cells,30,36
the adhesion between endothelial cells and polymorphonuclear leuko-
cytes or tumor cell lines,31 and osteoclast differentiation.37
The nature of ICOS-L-induced signals depends on the experimen-
tal system. So, whereas induction of IL-6 in mouse DC is dependent on
the p38MAPK,35 ICOS-L lowers ERK activation induced by E-selectin
or osteopontin.31 ICOS-L signaling also inhibited focal adhesion kinase
(FAK) tyrosine phosphorylation and induced lower levels of the Rac-1
activator -Pix.30,36 Last, ICOS-L enhancement of pattern recognition
receptor (PRR) signals was dependent on the cytoplasmic tail of ICOS-
L through recruitment and activation of the adaptor RACK1, and the
kinases PKC and JNK.20
The expression levels of ICOS-L are essential to regulate its func-
tions, and are subject to strict control. So, ICOS-L deficiency leads to
major defects in immune responses,13,34 and altered levels of ICOS-
L in humans or mice have significant effects on the development of
immune responses and autoimmune diseases.7,20,38–43 In naïve B lym-
phocytes activated by IL-4 or BCR stimuli, ICOS-L is downmodulated
within 24h through Ca++- and STAT-6-mediated mechanisms.44 This
phenomenon involved the disappearance of ICOS-L mRNA, and could
be blocked by CD40 signals.44 In addition, the interaction with ICOS+
cells or ICOS-coated beads also induces ICOS-L downmodulation from
the cell surface in a few hours.42,45
We show here that ICOS-L levels in different cells and cell lines
are drastically reduced within a fewminutes of interaction with ICOS-
expressing T cells. Previous data suggested that ICOS-induced down-
modulation of cell surface ICOS-L is the consequence of proteinase-
mediated “shedding” with the indirect or direct participation of
ADAM10andADAM17.40,45,46 However, althoughADAM10mediates
ICOS-induced ICOS-L shedding from B cells, a significant effect of
ADAM10 inhibitors on ICOS-L levels “in vitro” takes several hours, typ-
ically 20 to 24 hours.40,45,46 Rather, our results using inhibitors indi-
cate that proteinase mediated shedding does not have a major role in
the fast ICOS-mediated downmodulation of cell surface ICOS-L that
occurs within the first minutes of interaction. In contrast, we have
found other mechanisms for fast ICOS-mediated removal of cell sur-
face ICOS-L mediated in part by protein kinase C- (PKC), dynamin-
and lipid raft-dependent endocytosis that is largely independent on
chlatrin or caveolin, and also by ICOS-induced trans-endocytosis or
trogocytosis.
2 MATERIALS AND METHODS
2.1 Mice
C57BL/6J mice (WT) and ICOS-deficient mice (ICOS-KO, B6.129S1-
Icostm1Flv) aged eight to sixteen weeks were used. The mice were bred
and housed at the animal care facilities of the Centro de Investiga-
ciones Biológicas (CSIC, Madrid, Spain), under specific pathogen free
conditions. The experimental procedures were approved by the Ethics
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F IGURE 1 Modulation of ICOS-L from the cell surface involves internalization. (A).Cells of theB cell lymphomaM12.C3 expressing an ICOS-L
GFP fusionprotein (ICOS-LGFP+)were incubated for 20min at 37◦Calone (left), or co-incubatedwith ICOS-expressingCD4+D10Tcells (+ICOS+
CD4+, right), or with an ICOS– mutant of D10 (+ICOS– CD4+, center). Then, theywere stained for surface CD4 to identify the T cells, and analyzed
by multidimensional microscopy for ICOS-L GFP (green) or CD4 (red). Clumping of ICOS-L GFP in the presence of ICOS– cells (red bars) or ICOS+
cells (blue bars) was quantified as the number of GFP fluorescence clusters/cell (GFP clusters/Cell, top graph) or the % of cell area with green
fluorescence above threshold (%GFPhi area, bottom graph). (B).M12 ICOS-L GFP+ cells were co-incubated with ICOS– (left) or ICOS+ (right) D10
cells, and surface ICOS-L stained (red). The cells were analyzed by confocal microscopy for distribution of ICOS-L GFP (green) and surface ICOS-L
(red); colocalization was quantified as Manders (M1, M2) coefficients in the presence of cells lacking ICOS (ICOS–, red bars) or cells expressing
ICOS (ICOS+, blue bars). Differences were analyzed by the Student’s t test (**: p< 0.01; ***: p< 0.001)
and Animal Welfare Committees of CSIC and conducted according to
local, national and European Union guidelines under project license
PROEX181/15 (to J.M.R.) approved by theConsejería deMedio Ambi-
ente yOrdenación del Territorio, C.A.Madrid.
2.2 Spleen T and B cells
CD4+ spleen T cells from WT or ICOS-KO mice were activated with
2.5 µg/mL Concanavalin A for 72h; then isolated CD4+ T cell blasts
were expanded for further 48h with IL-2 as described in.47 To obtain
B cell blasts, spleen cells from ICOS-KO mice at 106 cells/mL in cul-
turemediumwere activated for 72hwith 30 µg/mL LPS. The cells were
thoroughly washed before use in internalization assays.
2.3 Cell lines
The cell lines used were the MHC Class II negative (I-A–) M12.C3
mouse B cell lymphoma,48 the mouse melanoma B16.F10, and the
CHO chinese hamster ovary tumor cell. They were grown in Click’s
medium supplemented with 10% heat-inactivated fetal bovine
serum and 50 µg/ml gentamicin (culture medium). The CD4+ICOS+
Th2 helper T cell line SR.D10 and its ICOS– mutant H4–.A5 were
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F IGURE 2 Modulation of ICOS-L from the cell surface involves
temperature-dependent internalization. (A).M12 ICOS-L GFP+ cells
were incubated for 15 min at 37◦C alone, or co-incubated with an
ICOS– mutant of D10 CD4+ T cells, or ICOS+ D10 cells, then stained
for ICOS-L and CD4, and analyzed by flow cytometry. M12 ICOS-L
GFP+ cells, gated as GFP+ CD4– cells, were analyzed for ICOS-L stain-
ing before (top panel) or after cell fixation (center), or after fixation
and permeabilization (lower panel). Graphs on the right show ICOS-L
fluorescence (FL) of M12 ICOS-L GFP+ cells incubated alone (orange
bars), or with ICOS– T cells (red bars), or ICOS+ T cells (blue bars).
White bars indicate FL in cells stained with control antibody. Aster-
isks indicate significant differences between conditions as determined
by one-way ANOVA. (B). ICOS-L modulation depends on temperature,
as shown by M12 ICOS-L GFP+ cells incubated for 20 min at 37◦C
alone, or co-incubated with ICOS+ D10 cells at 37◦C or at 4◦C, as indi-
cated. Cells were stained for ICOS-L and CD4, thenM12 ICOS-L GFP+
(GFP+ CD4– cells) were gated and analyzed for ICOS-L staining. Num-
bers inside thehistograms indicate thepercentageof positive cells. The
graph on the right shows FL inM12 ICOS-LGFP+ cells incubated alone
(red bar), or with ICOS+ T cells at 37◦C (blue bar) or 4◦C (light blue
bar). The white bar indicates FL in cells stained with control antibody.
Asterisks indicate significant differences between conditions as deter-
mined by one-way ANOVA. C. Analysis by immunoblot of cell lysates
from 0.5× 106 M12 ICOS-L GFP+ cells after incubation with 0.5× 106
ICOS+ D10 cells for 20min at 4◦Cor 37◦C, as indicated. Lysates of 106
cells each of D10 cells, or untransfected M12.C3 cells, or M12 ICOS-L
GFP+ cells, were included as controls. Blots were probed with ICOS-
L- and GFP-specific antibodies; blots probed with anti-Vav antibodies
were used as loading controls. Graphs (right) compare the corrected
O.D. values (Arbitrary Units) of bands of 80 and 125 kDa in lanes 5
(4◦C, light blue) and 6 (37◦C, blue) of the ICOS-L blot (top graph) and
theGFP blot (bottom graph). *: p< 0.05; **: p< 0.01; ***: p< 0.001. n.s.:
not significant differences between triplicate determinations fromone
representative experiment of three (A, B) or two experiments (C). per-
formedwith similar results
grown in culture medium supplemented with IL-2, IL-4, and IL-1, as
described.16,49,50
2.4 Antibodies and other reagents
Antibodies usedwere anti-CD4RM4-5-APC (eBioscience) andRM4-5-
AlexaFluor647 (BD Pharmingen), anti-CD19-FITC (ImmunoTools) and
anti-CD19-PE (eBioscience); anti-B7h (Anti-CD275HK5.3 andHK5.3-
PE, eBioscience); Rabbit polyclonal antibodies anti-ERK (C-14), anti-
Akt1/2 (H-136), and polyclonal goat anti-B7h (M-19) were from Santa
Cruz Biotechnology. Anti-GFP (Abcam, 6673), HRP-rabbit anti-goat Ig
(Dako, P0449) HRP-goat anti-rabbit Ig (Sigma, A-0545), goat anti-rat
IgG Alexa568 and Alexa648 conjugates (Molecular Probes, A11077,
A21247) were also used. FITC Cholera Toxin B (CTB) was from Sigma
(C1655); Biotin-CholeraToxinBandAlexa568-streptavidin conjugates
were from Life Technologies (C34779 and S11226). Rabbit mono-
clonal anti-phospho-Akt(Ser473) (D9E) antibody was fromCell Signal-
ing Technology.
Recombinant Mouse ICOS Fc Chimera was from R&D Systems
(ref. 168-CS). Bafilomycin A, Blebbistatin, Brefeldin A, Chloro-
quine, Chlorpromazine, Colchicine, Cycloheximide, Cystamine,
Cytocalasin B, Cytocalasin D, Dynasore, Genistein, LY294002,Methyl-
-Cyclodextrin, ML-7, PP-2, Phorbol Myristic acetate (PMA), and
SB 203580 were from Sigma. Bisindolylmaleimide I (Gö6850), Iono-
mycin, ROCK inhibitor H-1152, Ro-31-8220 (Bisindolylmaleimide IX),
U0126, and W-7 were from Calbiochem. The PI3-kinase inhibitors
A-66 and IC-87114, and FAK inhibitors PF-573228 and PF-562271
were from Selleckchem. The proteinase inhibitors used were the
-secretase inhibitor GM 6001, -Secretase Inhibitor IV, Dipeptidyl
peptidase IV Inhibitor from Calbiochem; Z-VAD-FMK, pAB GP DL
DA, 1,10-Phenantroline, and Phosphoramidon were from Sigma. The
specificity of these reagents are summarized in Tables 1 and S1.
2.5 Plasmids andmutagenesis
As expression vector for ICOS-L, the p-CMV6-Kan/Neo plasmid con-
taining the cDNA for mouse B7h was used (pB7h plasmid, Origene
TrueClone MC202216). Alternatively, the ICOS-L cDNA was ampli-
fied by PCR using primers and template cDNA prepared from mouse
spleen. The primers usedwere:
5′-GCAAAGCTTGCTCGCACCATGCAGCTAAAG-3′ (forward)
5′-GCAGGATCCGCGTGGTCTGTAAGTTCAAGC-3′ (reverse)
where Hind III and Bam HI sites are underlined, and the initial Met
codon is indicated in bold. The amplified fragment was subcloned in-
frame between theHind III andBamH1 sites of the pEGFP-N1plasmid
(Clontech) to generate plasmid pB7hGFP.
All pB7h and pB7hGFP mutants were generated with the
QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent).
Mutants in conserved cytoplasmic residues (ICOS-L Arg300-Ala,
ICOS-L Ser307-Ala, and ICOS-L Tyr308-Phe) were obtained using the
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TABLE 1 ICOS-induced ICOS-L downmodulation: Effect of inhibitors of endocytosis, cell cytoskeleton, protein kinase C, lysosomal function,







Chlorpromazine (50 µM) +/-
Caveolin-Mediated
Endocytosis
Genistein (100 µg/mL) +
Dynamin
GTPases/Endocytosis










Actin polymerization Cytochalasin D (10 µM) ++
Myosin ATPase Blebbistatin (30 µM) –
Myosin Light Chain Kinase ML-7 (10 µM) –
Tubulin (microtubule
growth)
Colchicine (20 µM) –
ROCK (Rho-dependent
kinase)
H-1152 (5 µM) –




Protein Kinase C ,  ,  , ,  Gö6850 (Bisindolylmaleimide I)
(1-10 µM)
++b








Low Temp (4◦C) - ++++
Respiratory Chain NaN3 (15mM) –
Ca++ , Mg++ Chelation EDTA (10mM) –










Bafilomycin A (0.5 µM) –
Lysosomal/Autophagy
inhibitor
Chloroquine (100 µM) –
Golgi Transport Brefeldin A (40 µM) –
Transglutaminase 2 Cystamine (500 µM) –
Calmodulin W-7 (25 µM) –





Src Tyr Kinases Fyn, Hck,
Lck
PP2 (5 µM) –c
MEK-1MAPK U0126 (2.5 µM) – b
P38MAPK SB203580 (1 µM) –b
(Continued on next page)
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TABLE 1 (Continued)







FAK Inhibitor I (10 µM) –c
Focal Adhesion Kinase
(FAK)
FAK Inhibitor II (10 µM) – c
PI3-K p110 A66 (1 µM) – c
PI3-K p110 IC87114 (1 µM) – c
PI3-K p110+ ETP-46321 (1 µM) – c
PI3-K (All) LY294002 (10 µM) –c
M12 ICOS-L GFP cells were incubated with ICOS+ D10 cells. ICOS-L staining in control assays of M12 ICOS-L GFP cells incubated with medium or with
H4–.A5 ICOS– D10mutant cells was taken as a reference.
a
Surface ICOS-L staining enhanced by 0–10% (–), 10–25% (+), 25–50% (++), 50–75% (+++), or > 75% (++++) of ICOS-L levels in M12 ICOS-L GFP cells




Incubation 60min, fixed ICOS+ cells.

















Truncated forms of ICOS-L lacking part or all the cytoplasmic
domain were obtained by mutation of Gly310 (pB7h ΔG310) or Arg300











To generate ICOS-L GFP fusion proteins lacking the intracytoplas-
mic sequence of ICOS-L, PCR were performed using pB7hGFP, one
sense oligonucleotide (pEGFP-N1 MCS F) containing the Xho I and
Hind III cloning sites of pEGFP-N1 and antisense oligonucleotides B7h
BamH I Gly310 R and B7h BamH I Arg300 R that introduced new
BamH I at residues Gly310 and Arg300:
pEGFP-N1MCS F:
5′ CTCAGATCTCGAGCTCAAGCT 3′
B7h BamHI Arg300 R:
5′ GGTGGATCCCTGTATATGATGAAGGAAACGAATGC 3′
The PCR products were subcloned between sites Xho I and
BamH I of pEGFP-N1 to obtain pB7hΔR300GFP. Mutant plasmids
were selected according to the manufacturer’s instructions, and their
sequence confirmed.
To obtain ICOSmCherry fusion proteins, ICOS cDNA was obtained
by RT-PCR using SR.D10 RNA as template and the oligonucleotides
ICOS HindIII F (sense) and ICOS EcoRI R (antisense), that included
newHindIII andEcoRI restriction sites (underlined) flanking themouse
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The PCR products were subcloned in the pcDNA3.1/V5-His-TOPO
plasmid (Invitrogen) and the sequence of the insert was confirmed.
Then, the HindIII-EcoRI fragment containing the ICOS sequence was
subcloned between theHindIII and EcoRI sites of the pEF1-mCherry-
N1 vector (Takara Clontech) to obtain the plasmid pICOSmCherry.
2.6 Transfection
Transfectants of different cell lines were generated by nucleofection
of 1.5-2 × 106 cells plus 2 µg of plasmid DNA in 100 µL of nucleofec-
tion solution V (Lonza) and programs L-13 (M12.C3), P-20 (B16.F10),
U-24 (CHO), and X-01 (H4–.A5) of the Nucleofector I device (Lonza),
according to the manufacturers’ instructions. After 24 h, the culture
medium was changed and Geneticin added. Cells were used within
48–72 h after transfection, or further expanded and selected for
expression of ICOS-L, ICOS-L GFP, mCherry, or ICOSmCherry by flow
cytometry and cloning of stable transfectant cells.
2.7 ICOS-Lmodulation assay
In a standard assay, ICOS-LGFP+ cells of theM12.C3 lymphoma trans-
fected with pB7hGFP (M12 ICOS-L GFP+ cells) and SR.D10 ICOS+
cells were washed and adjusted to 107 cells/ml in culture medium.
Then, 50 µL (0,5 × 106) of each cell suspension were mixed in round-
bottom 96 well plates and cultured for 15 min or the time indicated
at 37◦C in a CO2 incubator. All other procedures were strictly per-
formed in the cold. After washing with PBS/0.1% BSA/0.1% NaN3
(staining buffer), the cells were stained with anti-B7h-PE and anti-
CD4-APC. Control assays includedM12 ICOS-LGFP+ cells mixedwith
ICOS– mutant cells or with culturemedium aswell as stainingwith iso-
type IgG controls. The stained cells were washed and fixed with 1%
paraformaldehyde in PBS before flow cytometry acquisition in a Beck-
man Coulter FC-500 flow cytometer and analysis by FlowLogic soft-
ware, or in a BD LSRFortessaTM cytometer and the BD FACSDivaTM
software, or the FlowJo software (Tree Star, Ashland,OR). For assays in
thepresenceof inhibitors, ICOS-L-expressing cellswerepre-incubated
for 30minwith the inhibitor, and distributed inwells. ICOS+ cells were
then added, and the plates centrifuged in the cold. After removing the
supernatants, the cells were resuspended in 0.1 ml of culture medium
containing the corresponding inhibitor. As controls, cells were incu-
bated with medium containing the same volume of dimethyl sulfoxide
(DMSO), or the solvent used.
The same approach was used to assay ICOS-induced ICOS-L mod-
ulation in ICOS-L GFP+ (pB7hGFP) transfectants of the B16.F10
melanoma or the CHO chinese hamster ovary cell lines, or ICOSm-
Cherry transfectants of the ICOS– SR.D10 mutant H4–.A5, or B and
T cell blasts. Since the ICOS-L is sensitive to trypsin, when adherent
cells were used they were detached from culture plates by incubation
for 15min at 37◦C in 2mMEDTA/PBS and pipetting.Where indicated,
SR.D10 ICOS+ cells were previously fixed with 4% paraformalde-
hyde (5 min at 37◦C) and washed with cold staining buffer. To stain
both surface and intracellular ICOS-L, the cells were fixed with 4%
paraformaldehyde, permeabilizedwith saponin and stained in thepres-
ence of saponin as described in.51 Where needed, cell sorting was per-
formed using a BD FACS Aria ITM flow cytometer (BD Biosciences).
2.8 Cell lysis and Immunoblot
Cells were washed with PBS and lysed (1.5-2 × 107 cells/ml) in lysis
buffer (Tris/HCl 50mM, pH7,6,NaCl 150mM,1%TritónX-100, Cl2Mg
1 mM, EGTA 1 mM, Na3VO4 1 mM, plus a protease inhibitor cock-
tail (Selleckchem K4000)). After 15 min on ice, the lysates were cen-
trifuged (600 xg, 5 min) and the supernatants mixed v:v with 2xSDS
PAGE sample buffer. The proteins were separated in 10% PAGE gels
and immunoblot performed as described.16
2.9 Microscopy
Cells (0.3-1 × 105) were seeded on microscopy chamber wells (1
µ-Slide 8well, Ibidi) coated overnightwith poly-L-Lysine (1mg/ml, 4◦C)
and washed. The attached cells were fixed with 4% paraformaldehyde
in PBS (2 min at 37◦C), washed with staining buffer, and mounted with
ProLong Diamond antifademountant (Molecular Probes).
Where needed, intracellular staining was performed after perme-
abilization in seeded, fixed cells as described above.
Multidimensional microscopy was performed on a Leica AF6000
LX system microscope (Mannheim, Germany); images were captured
using a 40.0 × 0.75DRY objective lens with the Hg-arc lamp.
Confocal microscopy analysis was performed in a Leica TCS-SP2-
AOBS-UV ultraspectral confocal microscope. Immunofluorescence
analysis was done using a 63 × 1.4 objective lens at 0.5 µm intervals.
Signals from different fluorescent probes were taken in parallel. Image
processingwas performed using the ImageJ 1.54pNIHpublic software
and Adobe Photoshop (Adobe Systems, Mountain View, CA). Manders
thresholded colocalization coefficients (M1,M2)were calculated using
the ImageJ 1.54pNIH software.
2.10 Separation of detergent-insolublemembrane
microdomains
Detergent-insoluble microdomains enriched in glycosphingolipids and
cholesterol (DIM), were separated as described,52,53 with minor modi-
fications. Cells (0.5-1 × 108) were lysed in 1 ml of 0.5% Triton X-100 in
MBS buffer (25 mMMES, 150 mMNaCl, pH 6.5 1 mM EDTA Na3VO4
1 mM, and protease inhibitor cocktail, pH 6.5). The lysate was homo-
geneized with 10 strokes of a loose-fitting Dounce homogenizer, and
centrifuged 10min at 900 xg. The supernatantwasmixed v:vwith 85%
sucrose in MBS, set on a 12 ml ultracentrifuge tube and overloaded
with 5 ml of 35% sucrose in MBS and 5 ml of 5% sucrose in MBS. The
samples were centrifuged 16–18 h at 200.000 xg at 4◦C. Fractions of
1mlwere taken and analyzed forGM-1 content as an indicator ofDIM.
Proteins in the different fractions were separated by SDS-PAGE and
analysed by immunoblot.
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2.11 Statistics
Data were analyzed using the GraphPad Prism 5 software (GraphPad
Software, San Diego, CA, USA). Comparison of experimental groups
was performed with one-way or two-way ANOVA, or unpaired, two-
tailed Student´s t test. Results are expressed as the mean ± standard
error of themean (SEM). Statistical significance was set at p< 0.05.
3 RESULTS
3.1 ICOS / ICOS-L interaction induces fast surface
internalization of ICOS-L
Previous data have shown that interaction with ICOS reduces ICOS-L
levels in the cell surface.45 Part of the ICOS-L can be detected by ELISA
in the supernatant after three hours, in a proteinase-dependent pro-
cess that can be inhibited with the -Secretase inhibitor GM 6001.45
In agreement with these data, we observed that ICOS-L levels in the
surface of lymphoma cells expressing an ICOS-L GFP fusion protein
(M12 ICOS-L GFP+) were markedly reduced upon co-culture with
ICOS+ cells for less than 60 min (i.e., 20 min). This phenomenon
was ICOS-dependent, as no modulation was observed when ICOS–
D10 cell mutants were used. Surprisingly, our attempts to inhibit
ICOS-L modulation with the -Secretase inhibitor GM 6001, or other
proteinase inhibitors failed to significantly reduce fast ICOS-L disap-
pearance (Table S1). Similar downmodulation was observed in cells
expressing normal, wild-type ICOS-L instead of ICOS-L GFP, as well
as in assays determining ICOS-L expression in B cells after interac-
tion with T cell blasts from wild type or ICOS-deficient mice (Supple-
mentary Figure S1). These results suggested that proteinase-mediated
removal of ICOS-L was not the main mechanism involved in this phe-
nomenon, and that fast downmodulation can be induced using acti-
vated primary spleen cells.
We then searched for alternative mechanisms of surface ICOS-L
modulation, including internalization. Fluorescence microscopy analy-
sis of GFP distribution in M12 ICOS-L GFP+ cells before or after incu-
bation for 20 min with ICOS+ D10 cells indicated a clear change in
GFP distribution to form intracellular clumps, whereas GFP distribu-
tion was uniform upon incubation of the cells alone or in the presence
of cells that do not express ICOS (fig. 1A). Further evidence for inter-
nalization came from confocal microscopy studies showing that, in the
absence of ICOS stimulus, there was abundant surface ICOS-L which
co-localized with GFP. In contrast, the contact with ICOS-expressing
cells induced the appearance of GFP patches inside the cells with no or
low surface ICOS-L staining (fig. 1B). Modulation of ICOS-L run in par-
allel with ICOS-dependent intracellular signaling, as shown by strong
phosphorylation of Akt (Supplementary Figure S2).
In agreement with the above data, Figure 2 shows that the level of
ICOS-L staining after20min incubationofM12 ICOS-LGFP+ cellswith
ICOS+D10cellswas largely recoveredafter cell permeabilization, con-
firming the intracellular location of most ICOS-L under these condi-
tions (fig. 2A).
Interestingly, co-incubation of M12 ICOS-L GFP+ cells and ICOS+
D10 cells in the cold largely prevented modulation of surface ICOS-
L (fig. 2B). Yet, in the lysates of cells incubated at 37◦C there was
just a modest decrease in the amount of ICOS-L as compared to cells
incubated at 4◦C, as detected by immunoblot (compare lanes 5 and
6, Figure 2C, left). Immunoblot with GFP-specific antibodies yielded
similar results (lanes 5 and 6, Figure 2C, right). This is unlike one
would expect in the event of ICOS-L shedding, where the amount of
ICOS-L in lysates from cells at 37◦C should be comparatively much
lower than the amount of remaining intracellular GFP. As shown in
the figure, monomers as well as oligomers of ICOS-L were detected,
in agreement with previous data.54 Taken together, these data show
that internalization, rather than shedding, is the main mechanism
for the early removal of surface ICOS-L induced by ICOS in this
system.
3.2 ICOS-Lmodulation by live or fixed ICOS+ cells
As shown in Figure 3, ICOS-L modulation from the surface of the
M12 B cell lymphoma is a very fast process. According to the time
course, less than 50% of the initial ICOS-L remained available to anti-
body in the cell surface after 15 min of incubation with ICOS+ cells,
and remains low for up to 120 min (fig. 3A). Interestingly, although
some level of ICOS-Lmodulationwas observedwhen fixed ICOS+ cells
were used, the process was partial, slow and impaired when compared
to modulation induced by live ICOS+ cells at the times considered
(fig. 3B). To analyzewhether the internalized ICOS-L underwent prote-
olysis, we determined by immunoblot the molecular species present in
cell lysates before or after co-incubation for 90minwith ICOS+ T cells.
The data in Supplementary Figure S3 showno clear indication of prote-
olytic degradation upon internalization (Fig S3a, b). Then, we assessed
whether removing ICOS+ T cells by cell sorting after internalization
would allow re-expression of ICOS-L in the cell surface. The data in
Supplementary Figure S3c show that surface ICOS-L levels are readily
restored after 2h culture, but this requires “de novo” protein synthesis,
as surface ICOS-L remains low in the presence of Cycloheximide.
3.3 Role of conserved cytoplasmic residues in
ICOS-Lmodulation
To analyze the internalization mechanisms of ICOS-L, we searched for
internalization motifs in the cytoplasmic sequence of mouse ICOS-
L. Although some di-leucine motifs could be found in the cytoplas-
mic domain of ICOS-L of some mammalian species, neither these nor
other known internalization motifs were present in the mouse ICOS-
L sequence (See data in Table S2 for comparison of known mammalian
ICOS-L sequences). Nevertheless, the participation of endocyticmech-
anisms in ICOS-L modulation was analyzed using two approaches,
namely, themutation of ICOS-L sequence, and the use of inhibitors.
Comparison of ICOS-L sequences fromdifferent species shows that
a number of residues within the cytoplasmic domain are highly con-
served (Table S2). Particularly, a juxtamembrane sequence motif (R-X-
R-X(4-5)-SY) is frequently found in the sequences considered. In this
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F IGURE 3 ICOS-dependent modulation of cell surface ICOS-L is a fast process that is impaired by fixation of ICOS+ cells. (A).M12 ICOS-L
GFP+ cells were incubated at 37◦C for different times alone (closed symbols) or with ICOS+ D10 cells (open symbols), then stained in the cold for
ICOS-L and CD4. M12 ICOS-L GFP+ cells (GFP+ CD4– cells), were gated and analyzed for ICOS-L and GFP fluorescence. Data shown as per cent
ICOS-L+ cells (left panel), or mean ICOS-L fluorescence (middle panel), or mean GFP fluorescence (right panel). Asterisks indicate significant dif-
ferences between conditions as determined by two-way ANOVA (***: p< 0.001). (B).M12 ICOS-L GFP+ cells were incubated at 37◦C for different
times alone (closed circles, solid line) or with ICOS+ D10 live cells (open circles, dashed lines), or with fixed ICOS+ D10 cells (squares, dashed line),
then fluorescence analyzed and shown as in A). Symbols indicate significant differences (p < 0.001) in fluorescence of ICOS-L GFP+ cells in the
presence or absence of fixed ICOS+ cells (), or between ICOS-L GFP+ cells plus or minus ICOS+ live cells (***), or between ICOS-L GFP+ cells
plus live or fixed ICOS+ cells (###), as determined by two-way ANOVA
regard, Hedl et al. have shown that at least the Arg residues located
close to the membrane and the Ser residue play a functional role in
ICOS-L signaling in humanDC.20 Mutants ofmouse ICOS-L in residues
Arg300, Ser307 and Tyr308 were generated and expressed in M12.C3
lymphoma or B16 melanoma cells (see sequence in Figure 4A). As
shown in Figure 4B-D, the modulation of ICOS-L induced by ICOS+
cells was not impaired in these mutants. This suggests that, unlike the
signaling of ICOS-L described by Hedl et al. in human DC,20 changes
in these conserved aminoacids are not critical to fast ICOS-induced
ICOS-L internalization in themouse.
3.4 Effect of metabolic inhibitors on ICOS-L
modulation
Since mutation of these conserved residues did not give a clue
as to the mechanism(s) involved in ICOS-L internalization, further
analysis of the mechanisms involved was performed using a number
of reagents with potential effect on endocytosis. The results sum-
marized in Table 1 show that ICOS-L downmodulation was partially
dependent on theDynaminGTPase and sensitive to depletion ofmem-
brane cholesterol, as shown by the effect of Dynasore and methyl-
-cyclodextrin, respectively (Table 1, Figure 5). Inhibitors of clathrin-
(Chlorpormazine) or caveolin-mediated internalization (Genistein) had
minor effects on ICOS-L downmodulation (Table 1). On the other
hand, inhibitors of actin polymerization and protein kinase C sig-
nificantly inhibited ICOS-induced internalization (Table 1, Figure 6),
and low temperature blocked the phenomenon (Table 1, Figure 2). A
number of other reagents that inhibit endocytosis or other related
processes in other experimental systems, or are known to partici-
pate in ICOS-L signaling had no detectable effect, including inhibitors
of lysosomal function, autophagy, Calmodulin, as well as inhibitors
of Src and FAK tyrosine kinases, MAP kinases, and PI3 kinases
(Table 1).
3.5 ICOS-L is present in lipid rafts
The effect of cholesterol depletion on ICOS-L downmodulation sug-
gested a role for cholesterol-rich, detergent-resistant lipid rafts. Since
ICOS is largely absent from the lipid rafts,55 the effect could be medi-
ated by the ICOS-L. Indeed, separation ofM12 ICOS-LGFP cell lysates
by ultracentrifugation in discontinuous sucrose gradients and analy-
sis of the fractions by immunoblot confirmed that part of the ICOS-
L was present in the lipid raft-enriched (i.e. GM-1-enriched) fractions
(fig. 7).
Interestingly, mouse ICOS-L residues 294 to 303 (VSFIIYRRTR),
that includes part of the transmembrane domain, comprise a sequence
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F IGURE 4 Mutation of single conserved residues in the cytoplasmic domain of ICOS-L does not affect ICOS-induced downmodulation. (A).
Comparison of transmembrane (underlined) and cytoplasmic domains of mouse (Mo B7h, sequence: gi22137739) or human (Hu B7h, sequence:
gi426393243) ICOS-L. Conserved residues in bold are boxed. B.M12.C3 cells transfected with wild type mouse ICOS-L (M12 ICOS-L GFP+ WT
cells, top) or with a mutated form of ICOS-L (Arg300 to Ala, M12 ICOS-L GFP R300-A, bottom) were incubated at 37
◦C for 30 min with ICOS– (red
histogram) or ICOS+ D10 cells (blue histogram), then stained in the cold for ICOS-L and CD4, and ICOS-LGFP+ cells (GFP+ CD4– cells) were gated
and analyzed for surface ICOS-L. C.M12.C3 cells transfected with wild type mouse ICOS-L (M12 ICOS-L GFP+ WT cells, top) or with a mutated
ICOS-L (Ser307 to Ala, M12 ICOS-L GFP S307-A, bottom) were incubated with ICOS
– (red histogram) or ICOS+ D10 cells (blue histogram), and
stained, gated, and analyzed for surface ICOS-L, as in (B). D. B16.F10 cells were transfected with wild type mouse ICOS-L (B16 ICOS-L GFP+ WT
cells, top) orwith amutated ICOS-L (Tyr308 to Phe, B16 ICOS-LGFPY308-F, bottom)were incubated at 37
◦C for 30minwith ICOS– (red histogram)
or ICOS+ D10 cells (blue histogram), then stained in the cold, GFP+ CD4– B16.F10 cells were gated, and analyzed for surface ICOS-L. Grey his-
tograms are from cells stained with a control antibody. Numbers inside the histograms indicate the mean fluorescence from the graphs below.
Graphs in the bottom show the mean ICOS-L fluorescence in cells transfected with WT or mutant ICOS-L. Asterisks (**: p < 0.01; ***: p < 0.001)
indicate significant differences between samples as determined by one-way ANOVA of ICOS-L fluorescence between cells incubated with ICOS–
cells (red bars) or with ICOS+ cells (blue bars) from four (M12 ICOS-L GFP R300-A; B16 ICOS-L GFP Y308-F) or three (M12 ICOS-L GFP S307-A)
different clones.White bars represent data from cells stainedwith a control antibody
similar to Cholesterol Recognition/interaction Amino acid Consen-
sus (CRAC) sequence motifs ([L/V]-X(1-5)-Y-X(1-5)-[R/K]) or CRAC-
like sequence motifs ([L/V]-X(1-5)-F-X(1-5)-[R/K]) (EMBOSS: fuzzpro
(http://emboss.bioinformatics.nl/cgi-bin/emboss/fuzzpro). Thus, inter-
action with cholesterol might facilitate the presence of ICOS-L in lipid
rafts.
3.6 Modulation of ICOS-L lacking the cytoplasmic
tail
To further determine the basis for ICOS-induced ICOS-L downmodula-
tion, mutants were obtained lacking the cytoplasmic domain of ICOS-
L (ICOS-L GFP R300Δ). The ICOS-L R300Δ mutant lost Ser and Arg
residues that are important to huICOS-L function20 and participate in
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F IGURE 5 Effect on ICOS-induced downmodulation of the ICOS ligand of: (A). the Dynamin GTPase inhibitor Dynasore, or (B). membrane
cholesterol depletion with Methyl--cyclodextrin. M12.C3 cells transfected with wild type mouse ICOS-L GFP (M12 ICOS-L GFPWT) were incu-
bated at 37◦C for 15min with ICOS+ D10 cells in the presence of Dynasore orMethyl--cyclodextrin, as indicated. Then, the cells were stained in
the cold, M12 ICOS-L GFP cells were gated as GFP+ CD4– cells, and analyzed for surface ICOS-L levels. Numbers inside the histograms indicate
the percentage of ICOS-L positive cells. The graphs show the percentage of ICOS-L+ cells, or themean ICOS-L fluorescence, inM12 cells incubated
alone (-) or with ICOS+ D10 cells (+) in the absence (open bars) or the presence (black bars) of Dynasore or Methyl--cyclodextrin, as indicated.
Bars in the left (C). are data from cells stainedwith a control antibody. Asterisks (*: p< 0.05; ***: p< 0.001) indicate significant differences between
cells incubated with or without Dynasore or Methyl--cyclodextrin, as determined by two-way ANOVA. n.s.: not significant. Data from triplicate
determinations of one representative experiment of two experiments performedwith similar results
the CRAC motifs. These constructs were transfected into CHO cells,
and the transfectants were analyzed for surface ICOS-L expression
after interaction with ICOS+ cells. As shown in figure 7, removal of the
cytoplasmic domain barely inhibited ICOS-induced ICOS-L downmod-
ulation (fig. 7b). This suggests that lipid rafts can help in ICOS-L endo-
cytosis, but are not essential to the process. This, plus the results of
point mutation, indicated that neither membrane-proximal cytoplas-
mic residues, nor the VSFIIYRRTR CRACmotif are essential to ICOS-L
internalization.
3.7 Transfer of ICOS into ICOS-L expressing cells
duringmodulation
As an alternative or a complement to endocytosis, we examined trans-
endocytosis (trogocytosis) as a possible mechanism for ICOS-induced
ICOS-L internalization. This was shown, first, by the detection of ICOS
in the surfaceof ICOS-L+ cells after co-culturewith ICOS+ cells (fig. 8A,
lower left, blue histogram). This phenomenon run in parallel with
downmodulation not only of surface ICOS-L in ICOS-L+ cells (fig. 8A,
top left, blue histogram) but, more importantly, with downmodulation
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F IGURE 6 Effect of the inhibitor of actin polymerization Cytochalasin D (A). and the Protein Kinase C inhibitor Gö6850 (B). on the downmod-
ulation of ICOS-L induced by ICOS+ cells.
(A).M12 ICOS-L GFP cells were incubated at 37◦C for 15 min alone or with ICOS+ D10 cells in the presence or absence of Cytochalasin D. Cells
were stained and M12 ICOS-L GFP cells, gated as GFP+ CD4– cells, were analyzed for surface ICOS-L. Graphs show the percentage of ICOS-L+
cells, or the mean ICOS-L fluorescence, in M12 cells incubated alone (-) or with ICOS+ D10 cells (+) in the absence (open bars) or the presence
(black bars) of Cytochalasin D, as indicated. Bars in the left (C). are data from cells stained with a control antibody. Asterisks (**: p < 0.01) indicate
significant differences between cells incubated with or without inhibitor as determined by two-way ANOVA. n.s.: not significant. B.M12 ICOS-L
GFP cells were incubated at 37◦C for 15 min alone or with ICOS+ D10 cells in the presence of different concentrations of the Protein Kinase C
inhibitor Gö6850. Graphs represent the percentage of ICOS-L+ cells (left), or the mean ICOS-L fluorescence (center), or GFP fluorescence (right)
in M12 cells incubated without (closed symbols) or with ICOS+ D10 cells (open symbols). Asterisks (*: p < 0.05; **: p < 0.01; **: p < 0.001) indi-
cate significant differences between cells incubated with or without ICOS+ D10 cells, as determined by two-way ANOVA. Data from triplicate
determinations of one representative experiment of two experiments performedwith similar results
of surface ICOS in the ICOS+ Tcells (fig. 8B, left, blue histogram). These
phenomena could not be observed using control cells that did not
express ICOS-L (fig. 8A, lower right, blue histogram), or ICOS (fig. 8A,
red histograms), or in other surfacemarkers of T cells (i.e. CD4) (fig. 8B,
right, blue histogram).
To confirm the specific transfer of ICOS to ICOS-L expressing cells,
we used ICOS-deficient H4–.A5 cells transfected with plasmids cod-
ing for ICOSmCherry fusion proteins, or transfected with mCherry
vector alone. Cells transfected with ICOSmCherry vectors expressed
high levels of ICOS and mCherry, and possessed a characteristic fea-
ture of ICOS ligation, namely ICOS-induced changes in cells shape,
particularly cell elongation (Supplementary Figure S4). When ICOSm-
Cherry transfectants were co-incubated with cells expressing ICOS-L,
transfer of mCherry fluorescence to the GFP+ ICOS-L+ CHO cells was
observed (fig. 8C, left, blue histogram). In contrast, transfer of ICOSm-
Cherry fluorescence to cells lacking ICOS-L was negligible (fig. 8C,
left, red histogram), as was the transfer of red fluorescence from cells
expressing mCherry alone (fig. 8C, right). Confocal analysis of individ-
ual GFP+ ICOS-L+ M12 lymphoma cells incubated with ICOSmCherry
transfectants of the CD4+ ICOS-deficient cell line H4–.A5 confirmed
ICOS-specific internalization of ICOS-L GFP and co-localization of
ICOS-L GFP with ICOSmCherry at intracellular vesicles or juxtamem-
brane locations (fig. 8D, left). This was not observed using T cells trans-
fected with mCherry alone (fig. 8D, right). All these data indicate that
ARAGONESES-FENOLL ET AL. 13
F IGURE 7 ICOS-L is present in cholesterol-rich detergent-insoluble membrane lipid rafts, and role of the cytoplasmic domain and CRAC
motifs in ICOS-L internalization.
(A).M12 ICOS-L GFP cell lysates were ultracentrifuged in a sucrose gradient, and fractions from 2 (top) to 10 (bottom) were separated by SDS-
PAGE. Then, the presence of ICOS-L in each fraction was detected by immunoblot using anti-ICOS-L- or GFP-specific antibodies (top panels).
Membrane raftswere determinedusingCholera toxinB subunits to detect theGM1ganglioside,whereas fractions poor in lipid raftswere detected
using anti-Erk antibodies, as indicated (bottom panels). Numbers in the left indicate approximateMW in kDa.
(B). Partial sequence of mouse ICOS-L (MoB7h). The CRAC (cholesterol recognition/interaction amino acid consensus) sequence VSFIIYRRTR in
mouse ICOS-L is indicated in bold red letters, and includes part of the transmembrane domain (underlined). CHOcells transfected to express fusion
proteins of GFP and wild type mouse ICOS-L (CHO ICOS-L GFP WT) or ICOS-L lacking the cytoplasmic domain (CHO ICOS-L GFP R300Δ) were
incubated at 37◦C for 15 min with ICOS-deficient H4–.A5 cells (red histograms) or ICOS+ D10 cells (blue histograms), then stained in the cold for
ICOS-L and CD4. ICOS-L GFP cells (GFP+ CD4– cells) were gated and analyzed for surface ICOS-L. Grey histograms show fluorescence of cells
stained with a control antibody. Graphs in the right show the mean ICOS-L fluorescence in cells transfected withWT or four mutant CHO ICOS-L
GFP R300Δ clones. Asterisks (*: p < 0.05; **: p < 0.01) indicate significant differences of ICOS-L fluorescence between cells incubated with ICOS–
cells (red bars) or with ICOS+ cells (blue bars), as determined by one-way ANOVA.White bars are data from cells stained with a control antibody.
Data from one representative experiment of two experiments performedwith similar results
ICOS is taken inside and transferred to ICOS-L+ cells together with its
ligand.
4 DISCUSSION
This study analyzes the mechanisms involved in the fast disappear-
ance of ICOS-L from the surface of APC and other cells expressing
ICOS-L upon interaction with ICOS-expressing cells. Available data
indicate that a tight control of ICOS-L expression is needed for nor-
mal development of immune responses and to prevent autoimmune
diseases.20,34,38–40,56 In B lymphocytes, downmodulation of surface
ICOS-L can be induced by interaction with ICOS, and also by PKC,
cytokine and antigen signals.44,45 Surface ICOS-L levels are lower in
spleen or bone marrow cells from wild type as compared to cells
from ICOS-deficient mice (see i.e.12,23). This fact suggests that ICOS-
L levels in wild-type mice are maintained low in an ICOS-dependent
fashion, even though ICOS expression by T cells is very low under
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F IGURE 8 Transfer of ICOS during co-incubation of cells expressing ICOS and ICOS-L.
(A).CHO cells expressing a fusion protein of GFP andwild typemouse ICOS-L (ICOS-L GFP+ cells) downmodulate surface ICOS-L and express low
levels of ICOSwhen cultured in the presence of ICOS+ T cells. CHO ICOS-LGFP+ cellswere incubated at 37◦C for 30min alone (green histograms),
with ICOS-deficient T cells (H4–.A5 cells, red histograms), or with ICOS+ T cells (D10 cells, blue histograms), then stained in the cold for surface
CD4, ICOS-L, and ICOS, as indicated. Then, the CHO cells (GFP+CD4– cells) were gated, analyzed for surface ICOS-L, GFP (top panels), or ICOS
(lower left). ICOS expression in control CHO GFP transfectants lacking surface ICOS-L (GFP+ cells) in the same conditions is shown (lower right).
Histograms of cells stained with control isotype antibodies, or of control GFP– CHO cells are in grey. (B). Cells of the CD4+ ICOS+ D10 cell line
(gated as GFP–CD4+ cells) lose surface ICOS when co-incubated for 30 min with ICOS-L GFP+ CHO cells (blue histogram, left panel). This was
not observed upon co-incubation with control CHOGFP transfectants (red histogram) or with medium alone (green histogram). In contrast, other
T cell surface proteins like CD4 had minor changes in the same conditions (right panel). Histograms in grey show staining with control isotype
antibodies. (C).CHOcells expressing ICOS-LGFP can incorporate red fluorescencewhen co-incubatedwith T cell expressing ICOSmCherry fusion
protein (left panel, blue histogram). This is not found in control GFP-expressing cells (left panel, red histogram), or with cells expressing mCherry
alone (right panel, blue histogram). Furthermore, red fluorescence is similar in ICOS-L+ (right panel, blue histograms) or ICOS-L– CHO cells (right
panel, red histograms) incubatedwith control T cell expressingmCherry alone. Grey histograms represent red fluorescence in CHOcells alone. (D).
Confocal analysis of ICOS-L GFPM12 cells (green) co-incubated with T cell transfectants (CD4+, blue) expressing an ICOSmCherry fusion protein
(red) (left panels). ICOS-L GFP is found in the cell membrane and in intracellular vesicles, as shown in distinct z-slices or in combined projection (z-
stack). Furthermore, ICOS-L GFP M12 cells incorporate ICOSmCherry, detected as red fluorescence in juxtamembrane or intracellular sites that
co-localize with ICOS-L GFP (arrows). This is not observed in ICOS-L GFPM12 cells incubated with control T cell expressing mCherry alone (right
panels). Graphs show colocalization quantified as thresholded Manders (M1, M2) coefficients in the presence of T cells expressing ICOSmCherry
(white bars) or cells expressingmCherry (grey bars). **: p< 0.01, as determined by the Student’s t test
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steady state conditions “in vivo”. Removal of ICOS-L prevents ICOS-
mediated costimulatory signals of activated and differentiated ICOS+
T lymphocytes, including Tfh cells.17,26–28,32–34,56,57 In normal or
tumor cells of hematopoietic and non-hematopoietic origin that
express ICOS-L, ICOS-L downmodulation would suppress its own
signals.20,30,31,35–37
In B lymphocytes, ICOS-L downmodulation is induced by interac-
tion with ICOS, by PKC activators, or by anti-IgM antibodies.45 Inter-
estingly, PKC and anti-IgM induce ICOS-L shedding and release into
supernatants, that was dependent on -secretase activity. In contrast,
ICOS-induced ICOS-L downmodulation was not accompanied by effi-
cient ICOS-L shedding, and -secretase inhibition had a low effect on
ICOS-induced downmodulation.45 In agreement with these data, we
find that the -secretase inhibitor GM6001 had a negligible effect
on ICOS-L downmodulation in our system (Table S1). Furthermore,
our studies using inhibitors specific for a broad range of proteinase
activities confirm that sheddingmediated by -secretase or other pro-
teinases plays aminor role, if any, in early ICOS-induced ICOS-L down-
modulation (Table S1).
Our analysis of ICOS-induced reduction of surface ICOS-L show
that, instead, there is a fast internalization of ICOS-L, as ICOS-L
was readily detected inside the cells after ICOS-L downmodulation,
suggesting that it was endocytosed. This seems a physiological phe-
nomenon, as substantial amounts of ICOS-L have been found inside
naïve, memory, and germinal center B cells; ICOS-L can be rapidly
translocated to the surface during antigen-specific T:B cell interac-
tions in the germinal centers.58 We examined a number of factors
and molecules involved in different modes of endocytosis. From our
analysis, it follows that ICOS-L internalization was dependent on tem-
perature and actin cytoskeleton. The effect of inhibitors also indi-
cated a modest role for clathrin- and caveolin-dependent endocyto-
sis. Rather, ICOS-L endocytosis was mainly mediated by mechanisms
dependent on the GTPaseDynamin and sensitive to cholesterol deple-
tion. There is growing evidence for different mechanisms of endocy-
tosis that are sensitive to cholesterol depletion and lipid raft integrity,
yet some of them are largely independent on clathrin or caveolin but
dependent on dynamin.59,60 A possible role for raft-mediated endo-
cytosis is reinforced by the presence of one Cholesterol Recogni-
tion/interaction Amino acid Consensus motif (CRAC, [L/V]-X(1-5)-Y-
X(1-5)-[R/K]) in the sequence of mouse ICOS-L. CRAC motifs and
their reverse CARC ([R/K]-X(1,5)-Y-X(1,5)-[L/V]) motifs are important
to cholesterol-protein interaction and protein location in lipid rafts.
There are also CRAC-like and CARC-like sequence motifs that fulfill
the same function, but with Phenylalanine or even Tryptophan in the
place of Tyrosine.61,62 A search for these motifs in ICOS-L sequences
show that they are present in most transmembrane domains of ICOS-
L of mammals and other vertebrates, including human ICOS-L. Fur-
thermore, ICOS-L sequences from many different vertebrate species
often contain Cys residues at or close to the transmembrane domain
(see pages 3–4 in Supplementary Table S2); acylation (i.e. palmytoila-
tion) of these residuesmight also contribute to location in lipid rafts.63
Another factor that might favor ICOS-mediated cell-cell interaction
and fast endocytosis is the tendency of ICOS-L to oligomerize in solu-
tion or on the cell surface.54
Although inhibitors of protein kinase C partially prevented endocy-
tosis, and PKC can bind human ICOS-L and mediate ICOS-L signals,20
we did not find a clear effect of mutation of cytoplasmic residues
involved in PKC recruitment. In fact, complete removal of the cytoplas-
mic tail of ICOS-L did not block internalization. This, plus partial inter-
nalization using fixed ICOS-expressing cells suggested additional, com-
plementary mechanisms in ICOS-induced internalization, that might
include trans-endocytosis.
Indeed,we could detect specific transfer of ICOS to ICOS-L-bearing
cells upon interaction with ICOS+ cells. This would be an example
of trans-endocytosis, or trogocytosis, a phenomenon dependent on
actin cytoskeleton reorganization that has a well stablished role in
the control of immune processes through cell-cell contact.64 One
case for trans-endocytosis has been described in the CD28- or CTLA-
4-mediated transfer of CD80 and CD86 from APC to T cells. In
this case, control of CD28 signaling through trogocytosis involves
members of both theCD28and theB7 families.65,66 Trans-endocytosis
also works the other way, namely the transfer of cell surface proteins
and other material from T lymphocytes to APC, i.e. by means of “T cell
microvilli particles” (TMP). TMP are enriched in molecules including
TCR, CD2, or cytokines involved in APC-mediated activation.67 Inter-
estingly, ICOS ligation induces rapid, antigen-independent spreading
of T cells, with actin cytoskeleton reorganization, cell elongation, and
formation of lamellipodia- and filopodia-like structures.14–16,55 So, it
is tempting to speculate that ICOS-ICOS-L interactions might induce
effects similar to those described for TMP. Concerning the biological
consequences of ICOS-ICOS-L modulation from cell surfaces, it can
be foreseen that high ICOS levels could have a selective role in some
instances. Particularly interesting is the antigen-independent recruit-
ment of T follicular helper (Tfh) cells to germinal centers, a migration
that depends on ICOS interactionwith ICOS-L expressed by bystander
B lymphocytes.17 In this case, it can be hypothesized that those Tfh
lymphocytes with the highest levels of ICOS expression would be bet-
ter fit for migration.
Further complexity to the regulation of ICOS-ICOS-L interactions is
added by the recent discovery of two newproteins that can specifically
bind ICOS-L, namely the 53 integrin,68 and osteopontin.69 These
proteinsbind ICOS-Lat sitesdistinct fromthatof ICOS, and their effect
on ICOS-induced ICOS-L internalization and signaling deserves fur-
ther analysis.
5 CONCLUSIONS
The present study identifies important novel features in the regula-
tion of ICOS-L function through control of cell surface expression.
Thesemechanisms add to transcriptional regulation and shedding, that
occur at later moments. Taken together, the data stress the need for a
tight control of ICOS-L expression that is essential for the adequate
development and regulation of immune responses,20,34,39,56 for the
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control of migration in ICOS-L+ normal or tumor cells, for the differ-
entiation of dendritic cells or osteoclasts30,31,36,37,69 and normal renal
function.68 So, downmodulation of ICOS-L within minutes by ICOS,
or within hours by BCR or IL-4 stimuli, seems necessary to adequate
ICOS-L function,44,45 as is the blocking of ICOS-Lmodulation in B cells
by CD40 signals that contribute to germinal center development.44,57
Thus, fine-tuning of ICOS-L expression through distinctmechanisms at
different moments opens new therapeutic approaches in autoimmune
diseases and the control of tumor growth.
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